Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Stockholders Equity of $493.40 million for fiscal year 2025.
Dianthus Therapeutics, Inc. /DE/ Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $493.40M | +40.0% |
| 2024 | $352.48M | +108.7% |
| 2023 | $168.87M | +480.6% |
| 2022 | -$44.37M | -157.2% |
| 2021 | -$17.25M | -112.0% |
| 2020 | $143.91M | +1.9% |
| 2019 | $141.19M | -3.1% |
| 2018 | $145.65M | +445.8% |
| 2017 | -$42.12M | -374.6% |
| 2016 | -$8.87M | -2970.6% |
| 2015 | -$289.0K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $546.45M | +61.7% | +80.3% |
| June 30, 2025 | $303.08M | -15.4% | -7.8% |
| March 31, 2025 | $328.61M | -11.8% | -6.8% |
| December 31, 2024 | $352.48M | +108.7% | +4.3% |
| September 30, 2024 | $337.90M | +89.4% | -5.7% |
| June 30, 2024 | $358.22M | +682.8% | -3.9% |
| March 31, 2024 | $372.69M | +833.3% | +120.7% |
| December 31, 2023 | $168.87M | +480.6% | -5.3% |
- Dianthus Therapeutics, Inc. /DE/ showed an increase of +40.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2015–2025 period, Dianthus Therapeutics, Inc. /DE/’s stockholders equity has grown by 170827.0% (from -$289.0 thousand to $493.40 million).
- The most recent figure is from Dianthus Therapeutics, Inc. /DE/’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: